Answer

IFF Scent recovery drivers, H2 evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan for 2027

1) What are the drivers of Scent’s recovery?

Scent’s recovery is being driven by a combination of (a) improved execution and market share recovery in Consumer Fragrance, (b) stabilization and targeted management of Fine Fragrance volatility tied to the Middle East, and (c) a rebuilding/strengthening of R&D capability and pipeline health.

A. Fragrance Ingredients is a major near-term growth tailwind that should normalize

In Q2, Scent sales grew 8% to $665 million. ¹
The quarter’s performance was driven by double-digit growth in Fragrance Ingredients and high single-digit growth in Consumer Fragrance, while Fine Fragrance grew low single digits (inclusive of Middle East impact). ¹
Management attributes the strong Q2 in Fragrance Ingredients to strategic use of the synthetics portfolio to capture sales amid macro/supply chain disruptions and higher Brent crude prices, while also benefiting from a difficult year-ago comparison. ²
They expect Fragrance Ingredients to normalize going forward, shifting back toward higher-value-added ingredients vs traditional synthetics, with the sequencing that “it’s included in our forecast for the second half of the year.” ³²

Interpretation: While Fragrance Ingredients supports the overall Scent recovery in the near term, management is explicitly warning that the “easy comps/portfolio mix/synthetics capture” tailwind should fade as the business shifts toward higher-value natural products—so the recovery must increasingly rest on core Fine/Consumer Fragrance execution rather than ingredient swing factors. ³²

B. Fine Fragrance recovery is a volatility-management story tied to the Middle East

For Fine Fragrance, management describes uncertainty and volatility in the Middle East and says the team managed the challenges such that Fine Fragrance finished slightly positive when the quarter was expected to be down mid-single digits coming in. ²
For the second half, they expect “softer in Q3” and “stronger Q4,” translating to a mid-single-digit range growth on a second-half basis. ³
They also frame the Q3 setup as affected by a ~20% prior-year comp (Q3 last year grew 20%), reinforcing why recovery may look uneven quarter-to-quarter. ²

Interpretation: The Fine Fragrance recovery appears less like a straight-line rebound and more like normalization after disruption/large comps, with improvement building into Q4. ³²

C. Consumer Fragrance recovery is driven by rebuilding R&D capability, go-to-market, and market share gains

Management points to R&D and go-to-market rebuilding and an effort “to drive market share gains.” ³
They describe Consumer Fragrance second-half evolution as “low single-digit range” growth; they had a “really good Q2 … high single-digit” result expected to normalize. ³
In Q2 specifically, Scent’s Consumer Fragrance strength contributed to the overall segment growth, with Consumer Fragrance described as high single-digit increase within Scent’s Q2 mix. ¹

Interpretation: Consumer Fragrance recovery is framed as operational and commercial capability rebuilding (R&D pipeline + customer go-to-market execution) rather than just cyclical timing. ³

D. R&D capability has been materially strengthened after being behind

Management emphasizes progress in R&D pipeline quality and execution: “2.5 years ago … the R&D pipeline … was not what it should have been,” but today they believe they have a very strong R&D capability, including great perfumers developing leading-edge new Fine Fragrances and Consumer Fragrances and a great pipeline of molecules and delivery systems. ⁴
They also stress the business is committed to continuing to reinvest to “set ourselves apart,” linking innovation to growth and margin resilience over time. ⁵

Interpretation: The recovery is not only commercial; it is tied to restoring the innovation engine (pipeline depth + perfumer capability + delivery systems) to support new product wins and share gains—especially for Consumer Fragrance and Fine Fragrance post-volatility. ⁴⁵

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Fine Fragrance (Scent): softer Q3, stronger Q4; mid-single-digit H2 growth

Management expects Fine Fragrance to be softer in Q3 but stronger in Q4. ³
On a second-half basis, Fine Fragrance growth is guided to mid-single-digit range. ³
They also cite a large Q3 prior-year comparison (~20% growth last year), which contributes to why Q3 may appear weaker even if underlying progress continues. ²

Consumer Fragrance (Scent): normalize from strong Q2 to low single-digit H2 growth

Consumer Fragrance is expected to be in the low single-digit growth range in the second half. ³
The company had a really good Q2 with high single-digit growth, but expects that to normalize on a go-forward basis to low single-digit. ³

Fragrance Ingredients (context that affects “Scent recovery,” though not asked directly)

Fragrance Ingredients is described as strong in Q2, but management expects normalization going forward and “slightly under pressure” YoY due to this calibration (while still noting strategic progress shifting to higher-value naturals). ³
It is also explicitly expected to normalize in the second half (forecast baked in). ²

Bottom line for H2 evolution: Fine Fragrance should show a U-shaped pattern (Q3 softer, Q4 stronger) leading to mid-single-digit H2 growth, while Consumer Fragrance should cool from a strong Q2 back to low single-digit growth, supported by R&D/go-to-market rebuild and market share gain efforts. ³²

3) What is the plan for R&D to support 2027?

The excerpts don’t provide a granular “2027 R&D budget” or a specific milestone-by-milestone project list, but they do lay out (1) what was fixed, (2) what capabilities exist now, and (3) the strategic trajectory they believe will produce a stronger competitive position “next year and the year after” (which includes 2027).

A. R&D capability rebuilding: pipeline, molecules, delivery systems, and perfumer-led innovation

Management states that R&D capability was behind 2.5 years ago, but now there is a very strong R&D capability with leading-edge new Fine Fragrances and Consumer Fragrances plus a pipeline of molecules and delivery systems. ⁴
They are confident enough to describe perfumer output and pipeline strength as tangible assets driving recovery. ⁴

Implication for 2027: If the pipeline of new molecules/delivery systems is now “great,” R&D is positioned to convert into new launches and improved win rates over the multi-year horizon needed for fragrance innovation cycles. ⁴

B. R&D as part of the “circle”: reinvest → better growth → margin + continued reinvestment

Management explicitly links innovation reinvestment to durable performance: “innovation matters” and becomes a “circle where we make those investments, we get the better growth rate and ultimately allows us to … expand margin, but continue to reinvest.” ⁵
They describe a target reinvestment intensity: R&D as a percentage of sales in the 8% to 9% range that must be maintained to “critically continue to reinvest.” ⁵

Implication for 2027: Maintaining reinvestment intensity at that level (or within that framework) is their operating principle to support continued product development and competitive differentiation into later years. ⁵

C. Sequencing: ingredient transformation and competitive position “as we go into next year and the year after”

In the excerpts, the “R&D support” for 2027 is closely coupled with a broader innovation/portfolio strategy: the shift to higher-value natural products is underway and “will take a little bit more time,” and management believes that “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” ³

Implication for 2027: While this statement is in the context of Fragrance Ingredients performance calibration, it clearly signals a multi-year payoff window consistent with 2027’s role as part of the “year after next year” horizon. ³

Summary

Drivers of Scent recovery: strong execution and market normalization amid disruption (Fine Fragrance managed despite Middle East volatility), Consumer Fragrance rebuild efforts (R&D capability + customer go-to-market + market share gains), and Q2/near-term support from Fragrance Ingredients—though that tailwind is expected to normalize as mix shifts back toward higher-value ingredients. ³⁴²¹
Second-half evolution: Fine Fragrance is guided to mid-single-digit growth in H2 with Q3 softer and Q4 stronger, aided by the cadence of volatility and large prior-year comps. ³² Consumer Fragrance is expected to move from Q2 high single-digit down to low single-digit growth in H2 as performance normalizes. ³
R&D plan for 2027: management highlights that the R&D “engine” has been rebuilt (pipeline strength, perfumer-led leading-edge new products, molecules and delivery systems) and that innovation reinvestment is treated as a self-reinforcing cycle, with R&D intensity targeted in the 8%–9% of sales range, supporting a multi-year competitive position. ⁴⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Driven by Consumer Fragrance, H2 Outlook, and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery drivers, H2 evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan for 2027

1) What are the drivers of Scent’s recovery?

A. Fragrance Ingredients is a major near-term growth tailwind that should normalize

B. Fine Fragrance recovery is a volatility-management story tied to the Middle East

C. Consumer Fragrance recovery is driven by rebuilding R&D capability, go-to-market, and market share gains

D. R&D capability has been materially strengthened after being behind

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Fine Fragrance (Scent): softer Q3, stronger Q4; mid-single-digit H2 growth

Consumer Fragrance (Scent): normalize from strong Q2 to low single-digit H2 growth

Fragrance Ingredients (context that affects “Scent recovery,” though not asked directly)

3) What is the plan for R&D to support 2027?

A. R&D capability rebuilding: pipeline, molecules, delivery systems, and perfumer-led innovation

B. R&D as part of the “circle”: reinvest → better growth → margin + continued reinvestment

C. Sequencing: ingredient transformation and competitive position “as we go into next year and the year after”

Summary

References

Keep Reading

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

Keep Reading

Keep Reading

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

IFF's Scent Recovery Driven by R&D Upgrades, 2H Growth Outlook for 2027

IFF Scent Recovery Accelerates on Fragrance Ingredients, H2 Outlook, 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026; H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Driven by Fragrance Ingredients, R&D Push for 2027

IFF Scent Recovery Driven by R&D, H2 Outlook, 2027 Plan

IFF Scent Recovery Fueled by 2H Fine Fragrance Growth and 2027 R&D Push

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Guides Capex at 5–6% and R&D at 8–9% Post-Divestiture Growth